A role for the mu opioid receptor in the antidepressant effects of buprenorphine
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
&NA; Buprenorphine (BPN), a mixed opioid drug with high affinity for mu (MOR) and kappa (KOR) opioid receptors, has been shown to produce behavioral responses in rodents that are similar to those of antidepressant and anxiolytic drugs. Although recent studies have identified KORs as a primary mediator of BPN's effects in rodent models of depressive‐like behavior, the role of MORs in BPN's behavioral effects has not been as well explored. The current studies investigated the role of MORs in mediating conditioned approach behavior in the novelty‐induced hypophagia (NIH) test, a behavioral measure previously shown to be sensitive to chronic treatment with antidepressant drugs. The effects of BPN were evaluated in the NIH test 24 h post‐administration in mice with genetic deletion of the MOR (Oprm1−/−) or KOR (Oprk1−/−), or after pharmacological blockade with the non‐selective opioid receptor antagonist naltrexone and selective MOR antagonist cyprodime. We found that behavioral responses to BPN in the NIH test were blocked in Oprm1−/− mice, but not in Oprk1−/− mice. Both cyprodime and naltrexone significantly reduced approach latency at doses experimentally proven to antagonize the MOR. In contrast the selective MOR agonist morphine and the selective KOR antagonist nor‐BNI were both ineffective. Moreover, antinociceptive studies revealed persistence of the MOR antagonist properties of BPN at 24 h post‐administration, the period of behavioral reactivity. These data support modulation of MOR activity as a key component of BPN's antidepressant‐like effects in the NIH paradigm. HIGHLIGHTSOprm1−/− mice, but not Oprk1−/− mice, showed slower learning to approach palatable food.Oprm1−/− mice, but not Oprk1−/− mice, failed to respond to buprenorphine in the novelty‐induced hypophagia test.Buprenorphine and cyprodime antagonized mu opioid receptors.Buprenorphine and cyprodime reduced approach latency in the novelty induced hypophagia test.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., et al. (1996) · Nature · doi:10.1038/383819a0 · Cited by 1,722
Opioids excite dopamine neurons by hyperpolarization of local interneurons
Johnson, S., & North, R. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00483.1992 · Cited by 1,637
Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses
Filliol, D., Ghozland, S., Chluba, J., Martin, M., Matthes, H. W. D., Simonin, F., Befort, K., Gavériaux-Ruff, C., Dierich, A., LeMeur, M., et al. (2000) · Nature Genetics · doi:10.1038/76061 · Cited by 672
Exploring the opioid system by gene knockout
Kieffer, B. L., & Gavériaux-Ruff, C. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00008-4 · Cited by 620
The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors
Bruchas, M. R., Land, B. B., & Chavkin, C. (2010) · Brain Research · doi:10.1016/j.brainres.2009.08.062 · Cited by 544 · cited 1×
“In contrast, the kappa opioid receptor (KOR) and its endogenous ligand dynorphin are thought to mediate behavioral responses to aversive or stressful experiences [7,26].”
Antidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats
Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jones, R. M., Portoghese, P. S., & Carlezon, W. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046433 · Cited by 485
The effects of chronic antidepressant treatment in an animal model of anxiety
Bodnoff, S., Suranyi-Cadotte, B., Aitken, D., Quirion, R., & Meaney, M. (1988) · Psychopharmacology · doi:10.1007/bf00181937 · Cited by 437
Buprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346 · cited 2×
“BPN has been shown to treat depression in reatment-resistant patients [3,37,48] in small studies and opioid odulation by ALKS 5461, BPN combined with a MOR antagonist amidorphan to block BPN abuse potential, is under clinical trials 15].”
Yovell, Y., Bar, G., Mashiah, M., Baruch, Y., Briskman, I., Asherov, J., Lotan, A., Rigbi, A., & Panksepp, J. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040535 · Cited by 311
Social Defeat Stress-Induced Behavioral Responses are Mediated by the Endogenous Kappa Opioid System
McLaughlin, J. P., Li, S., Valdez, J., Chavkin, T. A., & Chavkin, C. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300872 · Cited by 253
Cited by
Pitsillou, E., Bresnehan, S. M., Kagarakis, E. A., Wijoyo, S. J., Liang, J., Hung, A., & Karagiannis, T. C. (2020) · Molecular Biology Reports · doi:10.1007/s11033-019-05129-3 · Cited by 206
Opioid system and human emotions
Nummenmaa, L., & Tuominen, L. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13812 · Cited by 178
The opioid system and the social brain: implications for depression and suicide
Lutz, P., Courtet, P., & Calati, R. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24269 · Cited by 53
“Animal studies investigating this combination of drugs have suggested that its antidepressive-like effects in mouse models of depression and social defeat (Browne et al. 2018) may implicate both MOR (Robinson et al. 2017) and KOR (Falcon et al. 2016; Falcon et al. 2014).”
BackgroundZhao, W.-N., Ghosh, B., Tyler, M., Lalonde, J., Joseph, N. F., Kosaric, N., Fass, D. M., Tsai, L.-H., Mazitschek, R., & Haggarty, S. J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00116 · Cited by 35
Metadata
- Authors
- Robinson, S. A., Erickson, R. L., Browne, C. A., & Lucki, I.
- Venue
- Behavioural Brain Research
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 319
- Pages
- 96-103
- ISSN
- 0166-4328 (ISSN-L)
- OpenAlex
- W2548430655
- Cited by
- 58
- References
- 15
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.